The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -10,086,687 | -10,687,830 | -7,585,692 | -11,165,091 |
| Stock-based compensation | 575,565 | 570,796 | 470,471 | 1,400,608 |
| Depreciation | 91,577 | 52,114 | 96,986 | 96,647 |
| Amortization of right of use asset | 39,189 | 38,517 | 37,869 | 42,368 |
| Loss on disposal of fixed assets | -34,153 | - | - | - |
| Realized gain on available-for-sale securities | 10,648 | - | - | - |
| Tax receivable | 725 | -12,379 | -21,564 | -2,025,564 |
| Prepaid expenses and other current assets | 866,595 | 191,348 | -50,572 | 145,953 |
| Other assets | - | - | - | 0 |
| Accounts payable and accrued expenses | 432,207 | -790,864 | 1,035,121 | 782,904 |
| Operating lease liability | -35,229 | -33,371 | -32,667 | -31,968 |
| Net cash used in operating activities | -9,827,193 | -11,029,607 | -5,905,776 | -6,994,921 |
| Purchase of property and equipment | 32,486 | 165,126 | 372,456 | 195,343 |
| Proceeds from the sale of short-term investments | 3,000,000 | - | - | - |
| Purchase of short-term investments | 7,768,350 | 6,480,860 | - | - |
| Net cash used in investing activities | -4,800,836 | -6,645,986 | -372,456 | -195,343 |
| Proceeds from exercise of stock options | 33,532 | 6,342 | - | - |
| Payments of deferred offering costs | 71,093 | -29,756 | 166,755 | - |
| Proceeds from exercise of stock warrants | - | 124,800 | - | - |
| Proceeds from sale of common stock, net of offering costs | - | 95,514,038 | 10,774,386 | 1,104,292 |
| Proceeds from exercise of stock options | - | - | 516 | 5,824 |
| Net cash provided by financing activities | -37,561 | 95,668,596 | 10,608,147 | 1,110,116 |
| Effect of foreign currency on cash | -12,813 | -11,745 | -20,552 | 36,139 |
| Net change in cash and cash equivalents | -14,678,403 | 77,981,258 | 4,309,363 | -6,044,009 |
| Cash and cash equivalents beginning of period | 93,928,566 | 15,947,308 | 17,681,954 | - |
| Cash and cash equivalents end of period | 79,250,163 | 93,928,566 | 15,947,308 | - |
Immix Biopharma, Inc. (IMMX)
Immix Biopharma, Inc. (IMMX)